Experience With Lucidis 124M Edof Iols
Published 2023 - 41st Congress of the ESCRS
Reference: PO0557 | DOI: 10.82333/pqxg-kk13
Authors: Zia ul Mazhry* 1 , Faiza Hassan 1 , Muhammad Abdullah Mazhry 2 , Laiba Asif 3
1Ophthalmology,WAPDA Teaching Hospital,Lahore,Pakistan, 2Ophthalmology,LRBT,Lahore,Pakistan, 3Ophthalmology,Acuity Eye Centre,Lahore,Pakistan
To evaluate the Lucidis 124M EDOF IOL for safety and post-op results in terms of intraoperative behaviour, improvement in the quality of vision and postoperative complication.
The study was conducted at WAPDA Teaching Hospital and Acuity Eye Centre, Lahore.
A prospective study was planned. 100 eyes with the diagnosis of cataract and no other comorbid ocular pathology were included in the study. Lucidis EDOF IOL was implanted during phacoemulsification cataract surgery over a period of 60 months from NOV 2017 to Oct 2022. Patients with intraoperative anterior or posterior capsular rip were excluded from the study. The post-operative assessment was performed one day 1, 1 week, 1 month, 3 months, 6 months and every year thereon. Quality of life was assessed by interviewing the patients at least 6 months postoperatively.
Minimum follows up was 6 months and ranged from 6-36 months. All 100 eyes had smooth Phaco and intra bag injection of IOLs with disposable injectors supplied by the distributor. Only 25 patients had bilateral implantation. 50 patients had uniocular Lucidis IOL implantation. Two patients had Refractive Rayner Bifocal in other eye. 16 patients had monofocal IOL in other eye. Two patients were there with only one eye and the rest of the 30 patients were phakic in other eye with varying degrees of lenticular changes. Uncorrected vision was 6/12 and BCVA was 6/6P. 17 patients had YAG, 6 months to 36 months post-operatively. 7 of the patients complained of mild photopsia and glare at night time.
The Lucidis EDOF technology IOL appears a safe, economical and effective option for phaco IOL surgery for the patients wanting less spectacle dependence after phaco cataract surgery. However, studies with bigger sample size and longer follow up are needed to establish this fact. Interestingly EDOF technology appears to minimise the risk of nighttime photopsia and glare. The compatible or preloaded IOL injection system is the need of the hour to save intraoperative manipulation and implantation of the IOL.